Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $682000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 42.4% to $682000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 7.18% decrease, with the full-year FY2025 number at $3.6 million, down 7.18% from a year prior.
  • Depreciation & Amortization (CF) was $682000.0 for Q4 2025 at Caribou Biosciences, up from $631000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.6 million in Q3 2023 to a low of $221000.0 in Q1 2021.
  • A 5-year average of $685150.0 and a median of $624000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 250.89% in 2023, then tumbled 46.39% in 2025.
  • Caribou Biosciences' Depreciation & Amortization (CF) stood at $273000.0 in 2021, then soared by 85.35% to $506000.0 in 2022, then skyrocketed by 46.25% to $740000.0 in 2023, then soared by 60.0% to $1.2 million in 2024, then plummeted by 42.4% to $682000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Depreciation & Amortization (CF) are $682000.0 (Q4 2025), $631000.0 (Q3 2025), and $1.2 million (Q2 2025).